SCHEMBL23728528

SCHEMBL23728528

c1cc(C2CC2)n2nccc2n1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
HTT P42858 1/20 0.51
IDO1 P14902 2/20 0.49
ALDH1A1 P00352 1/20 0.47
DGAT1 O75907 4/20 0.38
DYRK1A Q13627 1/20 0.35
PDE2A O00408 4/20 0.33
CHEK1 O14757 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CCNA1 P78396 1/20 0.33
PDE3B Q13370 2/20 0.32
PDE10A Q9Y233 2/20 0.32
PDE3A Q14432 1/20 0.32
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP9 Q86TI2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31579398 0.93 IDO1 (0.46) KDM4EHTTIDO1ALDH1A1DGAT1
SCHEMBL31579411 0.93 IDO1 (0.46) KDM4EHTTIDO1ALDH1A1DGAT1
SCHEMBL31579181 0.91 DGAT1 (0.48) KDM4EHTTIDO1ALDH1A1DGAT1
SCHEMBL21138822 0.88 IDO1 (0.44) KDM4EHTTIDO1ALDH1A1CHEK1
SCHEMBL17730058 0.85 IDO1 (0.53) KDM4EHTTIDO1ALDH1A1DGAT1
SCHEMBL21214004 0.83 DGAT1 (0.56) KDM4EHTTIDO1ALDH1A1DGAT1
SCHEMBL21214005 0.81 IDO1 (0.63) KDM4EHTTIDO1ALDH1A1DGAT1
SCHEMBL17730143 0.81 IDO1 (0.63) KDM4EHTTIDO1ALDH1A1DGAT1
SCHEMBL21214000 0.77 IDO1 (0.45) KDM4EHTTIDO1DGAT1
SCHEMBL31579389 0.76 IDO1 (0.38) KDM4EHTTIDO1ALDH1A1DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163066-A1 PROTACs of MALT1 TEGID THERAPEUTICS, INC. 2025-05-22 US disclosed
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163066-A1 PROTACs of MALT1 MALT1, BCL3, BCL9 KDM4E 428/4885HTT 819/4885IDO1 1144/4885
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885HTT 2464/4885IDO1 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.